Alzheimer’s disease therapies in phase III development 2025, by type
收藏Statista2026-04-11 收录
数据链接：
官方服务：
资源简介：
Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2025, by type
应用场景：
相关数据集
Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors
Objective To determine whether there are differences in age and sex distribution and presence of comorbidities between participants included in randomized controlled trials of acetylcholinesterase inh
NIAID Data Ecosystem80
The transition midpoint temperature (Tm) calculated from DSC curves of Aβ42 in absence and presence of doliroside A.
The transition midpoint temperature (Tm) calculated from DSC curves of Aβ42 in absence and presence of doliroside A.
Figshare2017-10-31 更新40
Dataset from A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-b
NIAID Data Ecosystem10
Additional file 1 of Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer’s disease
Additional file 1.
DataCite Commons2024-09-11 更新80
JNJ-67569762, A 2‑Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate
The discovery of a novel 2-aminotetrahydropyridine class of BACE1 inhibitors is described. Their pKa and lipophilicity were modulated by a pending sulfonyl group, while good permeability and brain pen
NIAID Data Ecosystem20
